The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial
Open accessAbstract
Importance: Patients with borderline-resectable pancreatic ductal adenocarcinoma have historically poor outcomes with surgery followed by adjuvant chemotherapy. Evaluation of a total neoadjuvant approach with highly active therapy is warranted. Objective: To evaluate the margin-negative (R0) resection rate in borderline-resectable pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX (fluorouracil, irinotecan, and oxaliplatin) therapy and individualized chemoradiotherapy. Design, Setting, and Participants: A single-arm, phase 2 clinical trial was conducted at a large academic hospital with expertise in pancreatic surgery from August 3, 2012, through August 31, 2016, among 48 patients with newly diagnosed, previously untreated, localized pancreatic cancer determined to be borderline resectable by multidisciplinary review, who had Eastern Cooperative Oncology Group performance status 0 or 1 and adequate hematologic, renal, and hepatic function. Median follow-up for the analysis was 18.0 months among the 30 patients still alive at study completion. Interventions: Patients received FOLFIRINOX for 8 cycles. Upon restaging, patients with resolution of vascular involvement received short-course chemoradiotherapy (5 Gy × 5 with protons) with capecitabine. Patients with persistent vascular involvement received long-course chemoradiotherapy with fluorouracil or capecitabine. Main Outcomes and Measures: The primary outcome was R0 resection rate; secondary outcomes were median progression-free survival (PFS) and median overall survival (OS). Results: Of the 48 eligible patients, 27 were men and 21 were women, with a median age of 62 years (range, 46-74 years). Of the 43 patients who planned to receive 8 preoperative cycles of chemotherapy, 34 (79%) were able to complete all cycles. Twenty-seven patients (56%) had short-course chemoradiotherapy, while 17 patients (35%) had long-course chemoradiotherapy. R0 resection was achieved in 31 of the 48 eligible patients (65%; 95% CI, 49%-78%). Among the 32 patients who underwent resection, the R0 resection rate was 97% (n = 31). Median PFS among all eligible patients was 14.7 months (95% CI, 10.5 to not reached), with 2-year PFS of 43%; median OS was 37.7 months (95% CI, 19.4 to not reached), with 2-year OS of 56%. Among patients who underwent resection, median PFS was 48.6 months (95% CI, 14.4 to not reached) and median OS has not been reached, with a 2-year PFS of 55% and a 2-year OS of 72%. Conclusions and Relevance: Preoperative FOLFIRINOX followed by individualized chemoradiotherapy in borderline resectable pancreatic cancer results in high rates of R0 resection and prolonged median PFS and median OS, supporting ongoing phase 3 trials. Trial Registration: ClinicalTrials.gov Identifier: NCT01591733.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Ryan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1404198 · Cited by 2,348
Self-citationMiwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
Hammel, P., Huguet, F., van Laethem, J.-L., Goldstein, D., Glimelius, B., Artru, P., Borbath, I., Bouché, O., Shannon, J., André, T., et al. (2016) · JAMA · doi:10.1001/jama.2016.4324 · Cited by 1,092
Suker, M., Beumer, B. R., Sadot, E., Marthey, L., Faris, J. E., Mellon, E. A., El-Rayes, B. F., Wang-Gillam, A., Lacy, J., Hosein, P. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00172-8 · Cited by 939
Self-citationBorderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease
Katz, M. H. G., Pisters, P. W. T., Evans, D. B., Sun, C. C., Lee, J. E., Fleming, J. B., Vauthey, N. J., Abdalla, E. K., Crane, C. H., Wolff, R. A., et al. (2008) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.12.020 · Cited by 827
Herman, J. M., Chang, D. T., Goodman, K. A., Dholakia, A. S., Raman, S. P., Hacker‐Prietz, A., Iacobuzio‐Donahue, C. A., Griffith, M. E., Pawlik, T. M., Pai, J. S., et al. (2015) · Cancer · doi:10.1002/cncr.29161 · Cited by 542
Katz, M. H. G., Shi, Q., Ahmad, S. A., Herman, J. M., Marsh, R. D. W., Collisson, E., Schwartz, L., Frankel, W., Martin, R., Conway, W., et al. (2016) · JAMA Surgery · doi:10.1001/jamasurg.2016.1137 · Cited by 448
Dias‐Santagata, D., Akhavanfard, S., David, S. S., Vernovsky, K., Kuhlmann, G., Boisvert, S. L., Stubbs, H., McDermott, U., Settleman, J., Kwak, E. L., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000070 · Cited by 396
Self-citationBreslin, T. M., Hess, K. R., Harbison, D. B., Jean, M. E., Cleary, K. R., Dackiw, A. P., Wolff, R. A., Abbruzzese, J. L., Janjan, N. A., Crane, C. H., et al. (2001) · Annals of Surgical Oncology · doi:10.1007/s10434-001-0123-4 · Cited by 352
Faris, J. E., Blaszkowsky, L. S., McDermott, S., Guimaraes, A. R., Szymonifka, J., Huynh, M. A., Ferrone, C. R., Wargo, J. A., Allen, J. N., Dias, L. E., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0435 · Cited by 278
Self-citationMarijnen, C. A. M., Nagtegaal, I. D., Kapiteijn, E., Kranenbarg, E. K., Noordijk, E. M., van Krieken, J. H. J. M., van de Velde, C. J. H., & Leer, J. W. H. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)04291-8 · Cited by 261
Staley, C. A., Lee, J. E., Cleary, K. R., Abbruzzese, J. L., Fenoglio, C. J., Rich, T. A., & Evans, D. B. (1996) · The American Journal of Surgery · doi:10.1016/s0002-9610(99)80085-3 · Cited by 228
Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer
Kim, J.-S., Js, K., Cho, M.-J., Song, K., & Yoon, W. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02856-0 · Cited by 195
Hong, T. S., Ryan, D. P., Borger, D. R., Blaszkowsky, L. S., Yeap, B. Y., Ancukiewicz, M., Deshpande, V., Shinagare, S. A., Wo, J. Y.-L., Boucher, Y., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.03.034 · Cited by 116
Self-citationArvold, N. D., Ryan, D. P., Niemierko, A., Blaszkowsky, L. S., Kwak, E. L., Wo, J. Y.-L., Allen, J. N., Clark, J. W., Wadlow, R. C., Zhu, A. X., et al. (2011) · Cancer · doi:10.1002/cncr.26633 · Cited by 67
Self-citation
Cited by
Park, W., Chawla, A., & O’Reilly, E. M. (2021) · JAMA · doi:10.1001/jama.2021.13027 · Cited by 1,882
Versteijne, E., Suker, M., Groothuis, K., Akkermans-Vogelaar, J. M., Besselink, M. G., Bonsing, B. A., Buijsen, J., Busch, O. R., Creemers, G.-J. M., van Dam, R. M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02274 · Cited by 1,082
Pancreatic cancer stroma: an update on therapeutic targeting strategies
Hosein, A. N., Brekken, R. A., & Maitra, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0300-1 · Cited by 950
Early Detection of Pancreatic Cancer: Opportunities and Challenges
Singhi, A. D., Koay, E. J., Chari, S. T., & Maitra, A. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.259 · Cited by 841
Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer
Ligorio, M., Sil, S., Malagon-Lopez, J., Nieman, L. T., Misale, S., Di Pilato, M., Ebright, R. Y., Karabacak, M. N., Kulkarni, A. S., Liu, A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.012 · Cited by 528
Self-citation
Metadata
- Authors
- Murphy, J. E., Wo, J. Y., Ryan, D. P., Jiang, W., Yeap, B. Y., Drapek, L. C., Blaszkowsky, L. S., Kwak, E. L., Allen, J. N., Clark, J. W., Faris, J. E., Zhu, A. X., Goyal, L., Lillemoe, K. D., DeLaney, T. F., Fernández-del Castillo, C., Ferrone, C. R., & Hong, T. S.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2018-07-01
- Volume
- 4
- Issue
- 7
- Pages
- 963
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2801077576
- Cited by
- 531
- References
- 18
- FWCI
- 21.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.